Overview Dividends

(KROS) Keros Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4923271013

Therapeutics, Clinical, Hematology, Cardiovascular, Neuromuscular

KROS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 56.83%
EPS Trend (3Y Correlation): 49.6%

KROS Revenue

Revenue Growth (3Y CAGR): 1744.71%
Revenue Trend (3Y Correlation): 71.2%

Description: KROS Keros Therapeutics October 23, 2025

Keros Therapeutics (NASDAQ: KROS) is a clinical-stage biopharma focused on diseases driven by dysregulated transforming growth factor-beta (TGF-β) signaling, targeting U.S. patients with unmet needs in hematology, pulmonary vascular, and neuromuscular disorders.

The lead candidate, KER-050, is in late-stage trials for cytopenias associated with myelodysplastic syndromes (MDS) and myelofibrosis, while KER-012 is in Phase II for pulmonary arterial hypertension (PAH) and related cardiovascular conditions, and KER-065 is in Phase I for neuromuscular diseases. A licensing partnership with Hansoh Healthtech grants Keros rights to develop and commercialize elritercept in China, potentially unlocking a large, rapidly growing market for TGF-β modulators.

As of the latest Q2 2024 filing, Keros held roughly $120 million in cash and marketable securities, supporting a projected cash runway of about 12 months at its current burn rate of $30 million per year; the company’s market cap hovers near $300 million, placing it in the lower-mid range of biotech valuations. The global TGF-β therapeutic market is estimated to reach $5 billion by 2028 (≈12 % CAGR), and overall biotech R&D spending is up ~8 % YoY, underscoring a favorable macro environment for innovative pipeline players.

For a deeper, data-driven look at KROS’s valuation and risk profile, the analyst commentary on ValueRay can provide useful context.

KROS Stock Overview

Market Cap in USD	464m
Sub-Industry	Biotechnology
IPO / Inception	2020-04-08

KROS Stock Ratings

Growth Rating	-53.4%
Fundamental	57.1%
Dividend Rating	-
Return 12m vs S&P 500	-78.8%
Analyst Rating	3.92 of 5

KROS Dividends

Currently no dividends paid

KROS Growth Ratios

Growth Correlation 3m	20.4%
Growth Correlation 12m	5.4%
Growth Correlation 5y	-48.9%
CAGR 5y	-30.55%
CAGR/Max DD 3y (Calmar Ratio)	-0.35
CAGR/Mean DD 3y (Pain Ratio)	-0.75
Sharpe Ratio 12m	0.67
Alpha	-91.68
Beta	0.972
Volatility	53.16%
Current Volume	1787.6k
Average Volume 20d	960.6k
Stop Loss	15.4 (-4.8%)
Signal	0.43

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (18.8m TTM) > 0 and > 6% of Revenue (6% = 14.0m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA 39.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 299.8% (prev 151.8k%; Δ -151.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 55.0m > Net Income 18.8m (YES >=105%, WARN >=100%)

Net Debt (-672.3m) to EBITDA (25.1m) ratio: -26.80 <= 3.0 (WARN <= 3.5)

Current Ratio 21.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (40.6m) change vs 12m ago 12.49% (target <= -2.0% for YES)

Gross Margin 99.42% (prev -409.6%; Δ 509.0pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 38.42% (prev 0.06%; Δ 38.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -7.48 (EBITDA TTM 25.1m / Interest Expense TTM -3.17m) >= 6 (WARN >= 3)

Altman Z'' -5.02

(A) 0.92 = (Total Current Assets 732.8m - Total Current Liabilities 34.7m) / Total Assets 757.2m

(B) -0.60 = Retained Earnings (Balance) -451.0m / Total Assets 757.2m

(D) -8.94 = Book Value of Equity -451.0m / Total Liabilities 50.4m

Total Rating: -5.02 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 57.07

1. Piotroski 5.50pt = 0.50

2. FCF Yield -25.45% = -5.0

3. FCF Margin 22.80% = 5.70

4. Debt/Equity 0.03 = 2.50

5. Debt/Ebitda -26.80 = 2.50

6. ROIC - WACC (= -5.76)% = -7.20

7. RoE 2.96% = 0.25

8. Rev. Trend 71.19% = 5.34

9. EPS Trend 49.64% = 2.48

What is the price of KROS shares?

As of November 07, 2025, the stock is trading at USD 16.17 with a total of 1,787,628 shares traded.
Over the past week, the price has changed by +7.58%, over one month by +3.52%, over three months by +12.21% and over the past year by -75.67%.

Is Keros Therapeutics a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Keros Therapeutics is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 57.07 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KROS is around 12.57 USD . This means that KROS is currently overvalued and has a potential downside of -22.26%.

Is KROS a buy, sell or hold?

Keros Therapeutics has received a consensus analysts rating of 3.92. Therefore, it is recommended to buy KROS.

Strong Buy: 5
Buy: 2
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the KROS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	23	42.2%
Analysts Target Price	23	42.2%
ValueRay Target Price	14.1	-12.7%

KROS Fundamental Data Overview November 02, 2025

Market Cap USD = 463.7m (463.7m USD * 1.0 USD.USD)
P/E Trailing = 47.5625
P/E Forward = 15.6495
P/S = 1.9914
P/B = 0.8954
Beta = 0.972
Revenue TTM = 232.8m USD
EBIT TTM = 23.7m USD
EBITDA TTM = 25.1m USD
Long Term Debt = 18.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.23m USD (from shortTermDebt, last quarter)
Debt = 18.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -672.3m USD (from netDebt column, last quarter)
Enterprise Value = -208.6m USD (463.7m + Debt 18.0m - CCE 690.2m)
Interest Coverage Ratio = -7.48 (Ebit TTM 23.7m / Interest Expense TTM -3.17m)
FCF Yield = -25.45% (FCF TTM 53.1m / Enterprise Value -208.6m)
FCF Margin = 22.80% (FCF TTM 53.1m / Revenue TTM 232.8m)
Net Margin = 8.06% (Net Income TTM 18.8m / Revenue TTM 232.8m)
Gross Margin = 99.42% ((Revenue TTM 232.8m - Cost of Revenue TTM 1.36m) / Revenue TTM)
Gross Margin QoQ = 97.96% (prev 99.84%)
Tobins Q-Ratio = -0.28 (set to none) (Enterprise Value -208.6m / Total Assets 757.2m)
Interest Expense / Debt = -17.67% (Interest Expense -3.17m / Debt 18.0m)
Taxrate = 6.75% (-2.22m / -32.9m)
NOPAT = 22.1m (EBIT 23.7m * (1 - 6.75%))
Current Ratio = 21.11 (Total Current Assets 732.8m / Total Current Liabilities 34.7m)
Debt / Equity = 0.03 (Debt 18.0m / totalStockholderEquity, last quarter 706.7m)
Debt / EBITDA = -26.80 (Net Debt -672.3m / EBITDA 25.1m)
Debt / FCF = -12.67 (Net Debt -672.3m / FCF TTM 53.1m)
Total Stockholder Equity = 635.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.48% (Net Income 18.8m / Total Assets 757.2m)
RoE = 2.96% (Net Income TTM 18.8m / Total Stockholder Equity 635.0m)
RoCE = 3.63% (EBIT 23.7m / Capital Employed (Equity 635.0m + L.T.Debt 18.0m))
RoIC = 3.48% (NOPAT 22.1m / Invested Capital 635.0m)
WACC = 9.24% (E(463.7m)/V(481.6m) * Re(9.60%) + (debt cost/tax rate unavailable))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 21.66%
[DCF Debug] Terminal Value 76.55% ; FCFE base≈53.1m ; Y1≈65.5m ; Y5≈111.7m
Fair Price DCF = 47.27 (DCF Value 1.44b / Shares Outstanding 30.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 49.64 | EPS CAGR: 56.83% | SUE: 0.77 | # QB: 0
Revenue Correlation: 71.19 | Revenue CAGR: 1745 % | SUE: 0.24 | # QB: 0

Additional Sources for KROS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle